NewsBenzingaMadrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra Benzinga 2026.10.06 12:14 (GMT+0) Open on Benzinga Other news Edwards Lifesciences Earnings Preview: What to Expect The Hartford Financial Services’ Quarterly Earnings Preview: What You Need to Know Cincinnati Financial Earnings Preview: What to Expect Keurig Dr Pepper Earnings Preview: What to Expect Earnings Preview: What to Expect From Universal Health Services’ Report Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD
Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD
